Navigation Links
Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Date:7/1/2011

GAITHERSBURG, Md., July 1, 2011 /PRNewswire/ -- Sigma-Tau Pharmaceuticals, Inc. announced the appointment of Dave Lemus as its new vice president of finance, effective July 1, 2011.  Lemus will join the leadership team at Sigma-Tau Pharmaceuticals U.S. corporate headquarters in Gaithersburg, Md.

For the past 13 years, Lemus served as chief financial officer of MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX), one of the Europe's leading biotechnology companies focused on fully human antibodies.  In this position, he held responsibilities for a variety of areas, including corporate development, technical operations, corporate legal, human resources, and public and investor relations.  In 1999, Lemus led the effort to take the company public, successfully completing Germany's first-ever biotech initial public offering.  For the next decade thereafter, he played a central role in helping grow the company into one of Europe's leading life science companies.

"I'm very pleased to become part of the Sigma-Tau growth story going forward as its new vice president of finance," commented Lemus.  "Moreover, Sigma-Tau's considerable expertise in rare diseases will continue to play a decisive role in propelling the company's high rate of growth and expansion over the coming years."

Prior to his role at MorphoSys AG, Lemus was a controller and operations manager at Hoffmann-La Roche, and preceding this position, he served as the treasurer of the Lindt Chocolate Company.

"As a leader in the development and commercialization of medicines for rare diseases, we have undergone tremendous growth in the past few years," said Gregg Lapointe, CEO, Sigma-Tau Pharmaceuticals, Inc.  "In looking to the future, it's imperative we have talented people like Dave to help Sigma-Tau continue to bring innovation to the field of rare diseases.  We're very pleased to welcome him to the team."

Sigma-Tau Pharmaceuticals, In
'/>"/>

SOURCE Sigma-Tau Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
2. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Regulatory affairs ... government, where regulations are often strict and legislation ... driving a demand for professionals who have a ... regulations across a product lifecycle and demonstrate its ... University of California, Irvine Extension , in ...
(Date:8/31/2015)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ), the nation,s largest ... Chairman & CEO, and Sean Whelan , CFO, will ... Hagerman and Mr. Whelan are scheduled to participate in the ... on Wednesday, September 9, 2015 at 1:45 PM ET. ... to participate in the Robert W. Baird 2015 Healthcare Conference ...
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated (NASDAQ: ... Qualcomm Life, Inc., is collaborating with ... care management solutions powered by Qualcomm Life,s 2net™ ... to enable continuous care, informed interventions and better ... at Qualcomm Life,s annual Connect 2015 ...
Breaking Medicine Technology:UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 2UC Irvine Extension Launches New Regulatory Affairs and Compliance Certificate Program 3Diplomat to Participate in Upcoming Investor Conferences 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... Eli Lilly and Company,(NYSE: LLY ) ... with the,European Medicines Agency (EMEA) for centralised review ... for the,first-line treatment of advanced non-small cell lung ... more than 85 countries as a,second-line, single agent ...
... insulin glargine, exenatide offered added benefits of, ... with metformin --, AMSTERDAM, Netherlands, Sept. 21 ... Eli Lilly and Company (NYSE: LLY ),today ... insulin glargine on beta-cell function, glycemic control and ...
Cached Medicine Technology:Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 2Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 3Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 4Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 5Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 6Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 7Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 8Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 9Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 10Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 11Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer 12One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 2One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 3One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 4One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 5One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 6One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function 7
(Date:8/31/2015)... ... August 31, 2015 , ... DR. LUCIANA ... Lagana (aka Dr. Luciana) received a total of three Silver Medal awards ... and Best (Dis)ability Film. Dr. Luciana co-wrote and co-produced this pilot with Del ...
(Date:8/31/2015)... ... August 31, 2015 , ... Wyoming Medical Center, ... software for its Clinical Documentation Improvement (CDI) and medical coding needs. Based on ... solution - ezCAC is an enterprise-level coding solution that combines CDI, Coding, Quality ...
(Date:8/31/2015)... New York (PRWEB) , ... August 31, 2015 , ... ... autumn, when play-offs and the World Series will dominate the sports world. Fans desire ... and eventually advance to the final series. For children, especially those who are too ...
(Date:8/31/2015)... ... ... On Saturday, May 30th, 2015, Best Drug Rehabilitation sponsored a benefit concert ... The purpose behind this concert was to raise money for music education programs in ... sponsorship of “Music with a Mission” helped with a portion of the cost of ...
(Date:8/31/2015)... Grove Village, IL (PRWEB) , ... August 31, 2015 , ... ... of new studies, Etymotic Research, maker of the BEAN™ personal sound amplifier, is offering ... using personal sound amplifiers as a way of coping with a variety of home ...
Breaking Medicine News(10 mins):Health News:Actor/Writer/Director/Psychology Professor Luciana Lagana Receives Three Wins at the 2015 Global Independent Film Awards for the TV Pilot Dr. Luciana on Aging and Falling 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:New Children's Baseball Series Offers Young Fans a Way to Celebrate the World Series 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 2Health News:Etymotic Offers Caregivers “7 Reasons to Care about Hearing Health” 3
... 4 August 2009 - The study of the neural ... the cortex the outer brain layers thought by ... at Brown University,s Department of Cognitive and Linguistic Sciences, ... ( http://www.elsevier.com/locate/cortex ), published by Elsevier, adds to evidence ...
... Aug. 4 Ferring Pharmaceuticals announced today that the ... trade name FIRMAGON(R) (degarelix for injection) for its prostate ... FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) ... Since initial market introduction under the generic name ...
... , , SAN FRANCISCO, Aug. 4 The ... available meniscus templates in California this past week, opening up a ... of portions damaged or missing meniscus cartilage, the fibrous shock absorber ... have only been able to remove, suture repair or replace the ...
... , ... Alaska takes top spot for 2nd year ... Fitness and Sports today recognized Alaska, Washington, D.C., Guam, Maryland and Wyoming as winners ... in the nation based on state population, once again placed first in this year,s ...
... hypertension, diabetes and smoking raise Alzheimer,s risk , ... are bad for your heart in the middle years ... smoking, diabetes -- are bad for your brain in ... in midlife were associated with an increased risk of ...
... , , RANCHO CORDOVA, Calif., Aug. ... announced today the results of their joint nationwide survey of nearly ... to 17-year-olds have difficulty seeing the classroom whiteboard/chalkboard, with more than ... though nearly half (45 percent) of the children in this age ...
Cached Medicine News:Health News:Looking at language 2Health News:Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment 2Health News:Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment 3Health News:Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment 4Health News:New Collagen Meniscus Implant Opens New Vista for Knee Repair 2Health News:New Collagen Meniscus Implant Opens New Vista for Knee Repair 3Health News:New Collagen Meniscus Implant Opens New Vista for Knee Repair 4Health News:President's Council Announces Top 5 Winners of 2009 National President's Challenge 2Health News:Midlife Heart Risk Factors Linked to Later Dementia 2Health News:Midlife Heart Risk Factors Linked to Later Dementia 3Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 2Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 3Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 4
Shielding's Economy Coat Apron offers the same features as our Standard Coat Apron with an open back allowing for freedom of movement, maximum flexibility and increased comfort....
Upper arm protection...
Lap pad used to protect pelvic regions...
Light and comfortable thyroid protection. The softest, most comfortable throid collar made. No neck irritating binding....
Medicine Products: